9,447
Total Claims
$2.6M
Drug Cost
1,065
Beneficiaries
$2,423
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+59%
Cost per patient vs peers
$2,423 vs $1,524 avg
+34%
Brand preference vs peers
18.3% vs 13.7% avg
Brand vs Generic
82% generic
Brand: 1,728 claims · $2.4M
Generic: 7,719 claims · $229K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 775 | $1.1M |
| Sacubitril/Valsartan | 309 | $522K |
| Empagliflozin | 211 | $331K |
| Rivaroxaban | 147 | $198K |
| Evolocumab | 54 | $60K |
| Ticagrelor | 35 | $40K |
| Ranolazine | 179 | $34K |
| Alirocumab | 22 | $28K |
| Metoprolol Succinate | 1,053 | $23K |
| Icosapent Ethyl | 32 | $22K |
| Icosapent Ethyl | 35 | $19K |
| Atorvastatin Calcium | 783 | $13K |
| Rosuvastatin Calcium | 488 | $13K |
| Diltiazem Hcl | 142 | $12K |
| Ezetimibe | 265 | $11K |
Prescribing Profile
49
Unique Drugs
$2.1M
Patient Profile
77
Avg Age
46%
Female
1.69
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About